All In Biotech

Drug Trial Radar · NCT05460455

A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants

A Phase Ic, Randomized, Double-blind, Placebo-controlled, Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0034 in Adult Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Oct 13, 2022

Primary completion

Jun 9, 2023

Study completion Dec 8, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following multiple-dose.

Conditions

  • Healthy

Interventions

  • Recombinant Humanized Anti-IL-36R Monoclonal antibody and PlaceboDrug

    HB0034 and Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with drug related adverse events (AEs)Time frame: up to 2000 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New zealand Clinical Research

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.